Hepatic decompensation and mortality in HCC treated with atezo-beva
Erman Akkus, Medical Oncologist at Ankara University, shared on X about an article titled “Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment” published on AASLD.
Authors: Celsa Ciro, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, Salvatore Battaglia, Marco Enea, Bernhard Scheiner, Antonio D’Alessio, Giulia F. Manfredi, Bernardo Stefanini, Naoshi Nishida, Peter R. Galle, Kornelius Schulze, Henning Wege, Roberta Ciccia, Wei-Fan Hsu, Caterina Vivaldi, Brooke Wietharn, Ryan Po-Ting Lin, Angelo Pirozzi, Tiziana Pressiani, Andrea Dalbeni, Leonardo A. Natola, Alessandra Auriemma, Cristina Rigamonti, Michela Burlone, Alessandro Parisi, Yi-Hsiang Huang, Pei-Chang Lee, Celina Ang, Thomas U. Marron, Matthias Pinter, Jaekyung Cheon, Samuel Phen, Amit G. Singal, Anuhya Gampa, Anjana Pillai, Natascha Roehlen, Robert Thimme, Arndt Vogel, Noha Soror, Susanna Ulahannan, Rohini Sharma, David Sacerdoti, Mario Pirisi, Lorenza Rimassa, Chun-Yen Lin, Anwaar Saeed, Gianluca Masi, Martin Schönlein, Johann von Felden, Masatoshi Kudo, Alessio Cortellini, Hong Jae Chon, Calogero Cammà and David James Pinato.
“Hepatic decompensation and mortality in HCC treated with atezo-beva.
Decompensation and disease progression are independent prognostic factors
- Decompensation HR: 19.04 (9.75-37.19)
- Progression HR: 9.91 (5.85-16.78)
Treatment of viral aetiology and management of cirrhosis are crucial.”
Source: Erman Akkus/X